Luminity

Procedural steps taken and scientific information after the authorisation

Application number	Scope	Opinion/ Notification[1] issued on	Commission Decision Issued[2] / amended on	Product Information affected[3]	Summary
II/0042/G	This was an application for a group of variations. B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place	26/04/2023	01/06/2023	SmPC	The SmPC section 6.5 has been updated as follows: 1.5 ml liquid in clear borosilicate Type I glass vial, closed with a chlorobutyl elastomeric stopper, and sealed with an aluminium crimp seal having a plastic flip-off button.

[1] Notifications are issued for type I variations and Article 61(3) notifications (unless part of a group including a type II variation or extension application or a worksharing application). Opinions are issued for all other procedures.
[2] A Commission decision (CD) is issued for procedures that affect the terms of the marketing authorisation (e.g. summary of product characteristics, annex II, labelling, package leaflet). The CD is issued within two months of the opinion for variations falling under the scope of Article 23.1a(a) of Regulation (EU) No. 712/2012, or within one year for other procedures.
[3] SmPC (Summary of Product Characteristics), Annex II, Labelling, PL (Package Leaflet).

	B.II.f.z - Stability of FP - Other variation B.II.e.1.z - Change in immediate packaging of the finished product - Other variation B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release/control, and secondary packaging, for biol/immunol medicinal products or pharmaceutical forms manufactured by complex manufacturing processes B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation				
PSUSA/2350/ 202112	Periodic Safety Update EU Single assessment - perflutren	01/09/2022	n/a		PRAC Recommendation - maintenance
II/0039	Update of section 4.4 of the SmPC in order to add a new warning on sickle cell anaemia, and update of section 4.8 of the SmPC to include the new ADRs Kounis Syndrome, sickle cell anaemia vaso-occlusive crisis based on reports in the post-marketing setting. The Package Leaflet is updated accordingly. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data	19/05/2022	01/06/2023	SmPC and PL	
IB/0038/G	This was an application for a group of variations. B.II.b.5.a - Change to in-process tests or limits applied during the manufacture of the finished	08/02/2022	n/a		

	product - Tightening of in-process limits B.II.b.4.a - Change in the batch size (including batch size ranges) of the finished product - Up to 10-fold compared to the originally approved batch size B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure				
IB/0037/G	This was an application for a group of variations. B.II.c.1.a - Change in the specification parameters and/or limits of an excipient - Tightening of specification limits B.II.c.2.d - Change in test procedure for an excipient - Other changes to a test procedure (including replacement or addition)	15/10/2021	n/a		
IB/0035/G	This was an application for a group of variations. B.II.e.6.b - Change in any part of the (primary) packaging material not in contact with the finished product formulation - Change that does not affect the product information B.II.e.2.a - Change in the specification parameters and/or limits of the immediate packaging of the finished product - Tightening of specification limits B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure	15/03/2021	n/a		

	(including replacement or addition) B.II.d.2.d - Change in test procedure for the finished product - Other changes to a test procedure (including replacement or addition) B.II.d.1.c - Change in the specification parameters and/or limits of the finished product - Addition of a new specification parameter to the specification with its corresponding test method B.II.d.1.c - Change in the specification parameters and/or limits of the finished product - Addition of a new specification parameter to the specification with its corresponding test method B.II.c.2.d - Change in test procedure for an excipient - Other changes to a test procedure (including replacement or addition) B.II.c.2.d - Change in test procedure for an excipient - Other changes to a test procedure (including replacement or addition) B.II.c.2.a - Change in test procedure for an excipient - Minor changes to an approved test procedure B.II.d.1.a - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits				
IA/0036	A.7 - Administrative change - Deletion of manufacturing sites	05/03/2021	16/09/2021	Annex II and PL	
II/0033	C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data	10/09/2020	16/09/2021	SmPC and PL	

IA/0034	B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place	14/07/2020	n/a		
IA/0032	B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place	17/03/2020	n/a		
IB/0031	C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation	12/02/2020	n/a		
IAIN/0029/G	This was an application for a group of variations. A.1 - Administrative change - Change in the name and/or address of the MAH B.II.b.2.a - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place B.II.b.2.c.1 - Change to importer, batch release arrangements and quality control testing of the FP - Replacement or addition of a manufacturer responsible for importation and/or batch release - Not including batch control/testing	20/09/2019	24/09/2020	SmPC, Annex II, Labelling and PL	
PSUSA/2350/ 201812	Periodic Safety Update EU Single assessment - perflutren	05/09/2019	n/a		PRAC Recommendation - maintenance

II/0026	C.I.13 - Other variations not specifically covered elsewhere in this Annex which involve the submission of studies to the competent authority	11/04/2019	n/a		
T/0027	Transfer of Marketing Authorisation	21/02/2019	11/03/2019	SmPC, Labelling and PL	
N/0025	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	04/05/2018	11/03/2019	PL	
IB/0024/G	This was an application for a group of variations. B.II.b.1.z - Replacement or addition of a manufacturing site for the FP - Other variation B.II.c.1.b - Change in the specification parameters and/or limits of an excipient - Addition of a new specification parameter to the specification with its corresponding test method B.II.c.1.z - Change in the specification parameters and/or limits of an excipient - Other variation B.II.c.4.a - Change in synthesis or recovery of a non-pharmacopoeial or novel excipient - Minor change	14/12/2016	n/a		
PSUSA/2350/ 201512	Periodic Safety Update EU Single assessment - perflutren	02/09/2016	n/a		PRAC Recommendation - maintenance
R/0021	Renewal of the marketing authorisation.	26/05/2016	15/07/2016	SmPC, Annex II, Labelling and PL	Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Luminity in the approved indication remains favourable and therefore recommended the renewal of the marketing

					authorisation with unlimited validity.
IAIN/0020	C.I.8.a - Introduction of or changes to a summary of Pharmacovigilance system - Changes in QPPV (including contact details) and/or changes in the PSMF location	03/08/2015	n/a		
IAIN/0019	C.I.9.b - Changes to an existing pharmacovigilance system as described in the DDPS - Change(s) in the safety database and/or major contractual arrangements for the fulfilment of PhV obligations, and/or change of the site undergoing PhV activities	14/08/2014	n/a		
II/0018	Update of section 4.8 of the SmPC, upon request by CHMP following the assessment of the renewal (R/11), to align the list of ADRs with the latest version of the MAH's Company Core Data Sheet (CCDS). The Package leaflet has been updated accordingly. In addition, the MAH took the opportunity to implement minor editorial changes in the annexes and wording in line with the latest QRD template. C.I.3.b - Change(s) in the SPC, Labelling or PL intended to implement the outcome of a procedure concerning PSUR or PASS or the outcome of the assessment done under A 45/46 - Change(s) with new additional data submitted by the MAH	22/05/2014	13/05/2015	SmPC, Labelling and PL	The following terms are included in the Luminity CCDS and are hereby introduced also in the EU SmPC: lip swelling, atrial fibrillation, cardiac ischaemia, supraventricular tachycardia, tongue disorder, hypertonia, loss of consciousness, bronchospasm, decreased oxygenation, hypoxia, rhinitis, upper airway swelling, throat tightness, facial swelling, abnormal vision, eye swelling and facial hypoaesthesia.
II/0017/G	This was an application for a group of variations. - To replace the finished product manufacturer.	18/12/2013	n/a		

	- To change the manufacturing process of the finished product. - To change the manufacturing process of the finished product. - To add a coating to the stopper top surface, which is not in contact with the product. - To replace the manufacturer of the Lipid Blend. - To add an alternative assay method for the Lipid blend. - To make changes in the manufacturing process for the lipid blend. B.II.b.1.c - Replacement or addition of a manufacturing site for the FP - Site where any manufacturing operation(s) take place, except batch release/control, and secondary packaging, for biol/immunol medicinal products or pharmaceutical forms manufactured by complex manufacturing processes B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation B.II.e.6.b - Change in any part of the (primary) packaging material not in contact with the finished product formulation - Change that does not affect the product information B.II.c.2.d - Change in test procedure for an excipient - Other changes to a test procedure (including replacement or addition) B.II.c.4.a - Change in synthesis or recovery of a non-pharmacopoeial or novel excipient - Minor change B.II.b.3.z - Change in the manufacturing process of the finished or intermediate product - Other variation				

	B.II.b.1.z - Replacement or addition of a manufacturing site for the FP - Other variation				
II/0014	Update of the product SPC. C.I.8.a - Introduction of a new Pharmacovigilance system - which has not been assessed by the relevant NCA/EMA for another product of the same MAH	24/05/2012	n/a		The variation (Type C.I.8 (a)) concerns a new Pharmacovigilance system as a consequence of the transfer of the Luminity Marketing Authorisation from Bristol-Myers Squibb to Lantheus MI UK Limited.
R/0011	Renewal of the marketing authorisation.	23/06/2011	13/09/2011	SmPC, Annex II, Labelling and PL	Based upon the data that have become available since the granting of the initial Marketing Authorisation, the CHMP considers that the benefit-risk balance of Luminity remains positive, but considers that its safety profile is to be closely monitored for the following reasons: A number of safety issues have been identified for Luminity, in particular some serious reactions are still occurring and the post marketing studies have provided little or no new information on the likely mechanism of these reactions. In addition, the product has not been on the EU market for almost three years. The product has just been re-introduced on the market on 15 June 2011. Thus, the CHMP decided that the MAH should continue to submit yearly PSURs until otherwise stated. Therefore, based upon the safety profile of Luminity, which requires submission of yearly PSURs, the CHMP concluded that the MAH should submit one additional renewal application in 5 years time.

IA/0012/G	This was an application for a group of variations. A.1 - Administrative change - Change in the name and/or address of the MAH A.5.b - Administrative change - Change in the name and/or address of a manufacturer of the finished product, including quality control sites (excluding manufacturer for batch release) A.5.b - Administrative change - Change in the name and/or address of a manufacturer of the finished product, including quality control sites (excluding manufacturer for batch release) B.II.b.2.b.1 - Change to batch release arrangements and quality control testing of the FP - Not including batch control/testing A.4 - Administrative change - Change in the name and/or address of a manufacturer or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS	14/06/2011	n/a	SmPC, Annex II, Labelling and PL	
II/0007	Update of Summary of Product Characteristics and Package Leaflet Update of Summary of Product Characteristics and Package Leaflet	23/07/2009	21/08/2009	SmPC and PL	This variation application is submitted following a safety review of serious unlabelled adverse reactions of Luminity. Following a request by the CHMP, the MAH is updating sections 4.2 and 4.4 to include additional safety information on cardiopulmonary reactions and section 4.8 to add ventricular arrhymias (primary ventricular tachycardia and premature ventricular contractions but also ventricular fibrillation asystole and severe respiratory distress. The Package Leaflet has been updated accordingly. In addition the MAH is also updating some contact details of local representatives.

T/0010	Transfer of Marketing Authorisation	12/06/2009	27/07/2009	SmPC, Annex II, Labelling and PL	Transder of the marketing authorisation from Bristol-Myers Squibb Pharma Belgium Sprl to Lantheus MI UK Ltd.
II/0009	Update of Detail Description of the Pharmacovigilance System (Pharmacovigilance) Changes to QPPV Update of DDPS (Pharmacovigilance)	22/01/2009	20/02/2009	Annex II	The Detailed Description of the Pharmacovigilance System has been updated (Version 3.0) to reflect the change of the Qualified Person for Pharmacovigilance (QPPV) as well as to notify other changes to the DDPS performed since the last approved version. Consequently, Annex II has been updated using the standard text including the new version number of the agreed DDPS.
II/0008	Update of Summary of Product Characteristics and Package Leaflet	23/10/2008	25/11/2008	SmPC and PL	Following a request by the CHMP, the MAH is updating sections 4.2, 4.5 and 5.2 of the SPC to reflect a lack of data in elderly and in patients with either renal or hepatic impairment. The Package Leaflet has been amended accordingly.
IB/0006	IB_19_b_Change in specification of an excipient - addition of new test parameter	12/12/2007	n/a		
IB/0005	IB_12_a_Change in spec. of active subst./agent used in manuf. of active subst. - tightening IB_13_b_Change in test proc. for active substance - other changes (replacement/addition)	19/11/2007	n/a		
II/0003	Update of Summary of Product Characteristics and Package Leaflet	20/09/2007	29/10/2007	SmPC and PL	This variation application is submitted following assessment of the 1st PSUR. Following a request by the CHMP, the MAH is updating sections 4.2, 4.4 and 4.8 of the Summary of Product Characteristics. The Package Leaflet has been updated accordingly. The MAH has also updated the contact details of the list of local representatives for Romania and

					Denmark in the Package Leaflet.
IB/0004	IB_38_c_Change in test procedure of finished product - other changes	24/09/2007	n/a		
N/0002	Minor change in labelling or package leaflet not connected with the SPC (Art. 61.3 Notification)	13/04/2007	n/a	PL	
IA/0001	IA_41_a_01_Change in pack size - change in no. of units within range of appr. pack size	05/01/2007	05/01/2007	SmPC, Labelling and PL	